{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:08:57Z","timestamp":1791248937214,"version":"4.1.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In earlier work, we showed that adeno-associated virus\u2013mediated delivery of a Factor IX gene to skeletal muscle by direct intramuscular injection resulted in therapeutic levels of circulating Factor IX in mice. However, achievement of target doses in humans proved impractical because of the large number of injections required. We used a novel intravascular delivery technique to achieve successful transduction of extensive areas of skeletal muscle in a large animal with hemophilia. We provide here the first report of long-term (&amp;gt; 3 years, with observation ongoing), robust Factor IX expression (circulating levels of 4%-14%) by muscle-directed gene transfer in a large animal, resulting in essentially complete correction of the bleeding disorder in hemophilic dogs. The results of this translational study establish an experimental basis for clinical studies of this delivery method in humans with hemophilia B. These findings also have immediate relevance for gene transfer in patients with muscular dystrophy.<\/jats:p>","DOI":"10.1182\/blood-2004-07-2908","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T01:32:57Z","timestamp":1097631177000},"page":"3458-3464","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":128,"title":["Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model"],"prefix":"10.1182","volume":"105","author":[{"given":"Valder R.","family":"Arruda","sequence":"first","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansell H.","family":"Stedman","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Nichols","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Haskins","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nicholson","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B.","family":"Couto","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"High","sequence":"additional","affiliation":[{"name":"From the Hematology Division, Department of Pediatrics, and the Howard Hughes Medical Institute, Children's Hospital of Philadelphia, PA; the Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; the Francis Owen Blood Research Laboratory, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill; the School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA; andAvigen, Inc,Alameda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223485930900_REF1","doi-asserted-by":"crossref","unstructured":"Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med. 1999;5: 56-63.","DOI":"10.1038\/4743"},{"key":"2020021223485930900_REF2","doi-asserted-by":"crossref","unstructured":"Herzog R, Hagstrom N, Kung S, et al. Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV. Proc Natl Acad Sci U S A. 1997;94: 5804-5809.","DOI":"10.1073\/pnas.94.11.5804"},{"key":"2020021223485930900_REF3","doi-asserted-by":"crossref","unstructured":"Arruda V, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood. 2001;97: 130-138.","DOI":"10.1182\/blood.V97.1.130"},{"key":"2020021223485930900_REF4","doi-asserted-by":"crossref","unstructured":"Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002;13: 1281-1291.","DOI":"10.1089\/104303402760128513"},{"key":"2020021223485930900_REF5","doi-asserted-by":"crossref","unstructured":"Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72: 1438-1445.","DOI":"10.1128\/JVI.72.2.1438-1445.1998"},{"key":"2020021223485930900_REF6","doi-asserted-by":"crossref","unstructured":"Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24: 257-261.","DOI":"10.1038\/73464"},{"key":"2020021223485930900_REF7","doi-asserted-by":"crossref","unstructured":"Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101: 2963-2972.","DOI":"10.1182\/blood-2002-10-3296"},{"key":"2020021223485930900_REF8","doi-asserted-by":"crossref","unstructured":"Arruda V, Schuettrumpf J, Herzog R, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 2004;103: 85-92.","DOI":"10.1182\/blood-2003-05-1446"},{"key":"2020021223485930900_REF9","doi-asserted-by":"crossref","unstructured":"Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther. 2001;4: 586-592.","DOI":"10.1006\/mthe.2001.0491"},{"key":"2020021223485930900_REF10","doi-asserted-by":"crossref","unstructured":"Greelish J, Su L, Lankford E, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 1999;5: 439-443.","DOI":"10.1038\/7439"},{"key":"2020021223485930900_REF11","doi-asserted-by":"crossref","unstructured":"Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A. 1989;86: 10095-10099.","DOI":"10.1073\/pnas.86.24.10095"},{"key":"2020021223485930900_REF12","doi-asserted-by":"crossref","unstructured":"Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4: 192-200.","DOI":"10.1006\/mthe.2001.0442"},{"key":"2020021223485930900_REF13","doi-asserted-by":"crossref","unstructured":"Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001;4: 201-210.","DOI":"10.1006\/mthe.2001.0441"},{"key":"2020021223485930900_REF14","doi-asserted-by":"crossref","unstructured":"Russell K, Olsen E, Raymer R, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003;102: 4393-4398.","DOI":"10.1182\/blood-2003-05-1498"},{"key":"2020021223485930900_REF15","doi-asserted-by":"crossref","unstructured":"Pruchnic R, Cao B, Peterson Z, et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther. 2000;11: 521-536.","DOI":"10.1089\/10430340050015716"},{"key":"2020021223485930900_REF16","doi-asserted-by":"crossref","unstructured":"Vrouenraets B, Klaase J, Nieweg O, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998;14: 224-231.","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<224::AID-SSU6>3.0.CO;2-A"},{"key":"2020021223485930900_REF17","doi-asserted-by":"crossref","unstructured":"Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999;10: 1735-1737.","DOI":"10.1089\/10430349950017734"},{"key":"2020021223485930900_REF18","doi-asserted-by":"crossref","unstructured":"Kren B, Bandyopadhyay P, Steer C. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA\/DNA oligonucleotides. Nat Med. 1998;4: 274-275.","DOI":"10.1038\/nm0398-285"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003;9: 1020-1025.","DOI":"10.1038\/nm899"},{"key":"2020021223485930900_REF20","doi-asserted-by":"crossref","unstructured":"Chao H, Mansfield S, Bartel R, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003;9: 1015-1019.","DOI":"10.1038\/nm900"},{"key":"2020021223485930900_REF21","doi-asserted-by":"crossref","unstructured":"Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16: 270-276.","DOI":"10.1038\/ng0797-270"},{"key":"2020021223485930900_REF22","doi-asserted-by":"crossref","unstructured":"Gallo-Penn A, Shirley P, Andrews J, et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice. Hum Gene Ther. 1999;10: 1791-1802.","DOI":"10.1089\/10430349950017473"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Gallo-Penn A, Shirley P, Andrews J, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood. 2001;97: 107-113.","DOI":"10.1182\/blood.V97.1.107"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Lozier JN, Csako G, Mondoro T, et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther. 2002;13: 113-124.","DOI":"10.1089\/10430340152712665"},{"key":"2020021223485930900_REF25","doi-asserted-by":"crossref","unstructured":"Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001;3: 708-722.","DOI":"10.1006\/mthe.2001.0330"},{"key":"2020021223485930900_REF26","doi-asserted-by":"crossref","unstructured":"Raper S, Chirmule N, Lee F, et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80: 148-158.","DOI":"10.1016\/j.ymgme.2003.08.016"},{"key":"2020021223485930900_REF27","doi-asserted-by":"crossref","unstructured":"VandenDriessche T, Vanslembrouck V, Goovaerts I, et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A. 1999;96: 10379-10384.","DOI":"10.1073\/pnas.96.18.10379"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Garcia-Martin C, Chuah MK, Van Damme A, et al. Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. J Gene Med. 2002;4: 215-223.","DOI":"10.1002\/jgm.248"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Van Damme A, Chuah MK, Dell'accio F, et al. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats. Haemophilia. 2003;9: 94-103.","DOI":"10.1046\/j.1365-2516.2003.00709.x"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood. 2000;96: 1173-1176.","DOI":"10.1182\/blood.V96.3.1173"},{"key":"2020021223485930900_","doi-asserted-by":"crossref","unstructured":"Reddy PS, Sakhuja K, Ganesh S, et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther. 2002;5: 63-73.","DOI":"10.1006\/mthe.2001.0510"},{"key":"2020021223485930900_REF32","doi-asserted-by":"crossref","unstructured":"Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther. 2003;8: 495-500.","DOI":"10.1016\/S1525-0016(03)00168-0"},{"key":"2020021223485930900_REF33","unstructured":"Biological Response Modifiers Advisory Committee. Issues pertaining to inadvertent germline transmission of gene transfer vectors. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/02\/briefing\/3855B2_01.doc. Accessed May 10, 2002."},{"key":"2020021223485930900_REF34","doi-asserted-by":"crossref","unstructured":"Boyce N. Trial halted after gene shows up in semen. Nature. 2001;414: 677.","DOI":"10.1038\/414677a"},{"key":"2020021223485930900_REF35","doi-asserted-by":"crossref","unstructured":"Aledort K, Levine P, Hilgartner M. A study of liver biopsies and liver disease among hemophiliacs. Blood. 1985;66: 367-372.","DOI":"10.1182\/blood.V66.2.367.367"},{"key":"2020021223485930900_REF36","doi-asserted-by":"crossref","unstructured":"Hanley J, Jarvis L, Andrews J. Investigation of chronic hepatitis C infection in individuals with haemophilia. Br J Haematol. 1996;94: 159-165.","DOI":"10.1046\/j.1365-2141.1996.6192064.x"},{"key":"2020021223485930900_REF37","unstructured":"High KA, Manno CS, Sabatino DE, et al. Immune responses to AAV and to Factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B. Blood. 2003;102: 154a-155a."},{"key":"2020021223485930900_REF38","doi-asserted-by":"crossref","unstructured":"Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotype correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99: 2670-2676.","DOI":"10.1182\/blood.V99.8.2670"},{"key":"2020021223485930900_REF39","doi-asserted-by":"crossref","unstructured":"Green PM, Montandon AJ, Ljung R, et al. Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity. Br J Haematol. 1991;78: 390-397.","DOI":"10.1111\/j.1365-2141.1991.tb04453.x"},{"key":"2020021223485930900_REF40","doi-asserted-by":"crossref","unstructured":"Ljung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol. 2001;113: 81-86.","DOI":"10.1046\/j.1365-2141.2001.02759.x"},{"key":"2020021223485930900_REF41","doi-asserted-by":"crossref","unstructured":"Xiao W, Chirmule N, Berta S, McCullough B, Gao GP, Wilson J. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73: 3994-4003.","DOI":"10.1128\/JVI.73.5.3994-4003.1999"},{"key":"2020021223485930900_REF42","doi-asserted-by":"crossref","unstructured":"Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther. 2001;4: 217-222.","DOI":"10.1006\/mthe.2001.0449"},{"key":"2020021223485930900_REF43","doi-asserted-by":"crossref","unstructured":"Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99: 11854-11859.","DOI":"10.1073\/pnas.182412299"},{"key":"2020021223485930900_REF44","doi-asserted-by":"crossref","unstructured":"Gao G, Lebherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004;103: 3300-3302.","DOI":"10.1182\/blood-2003-11-3852"},{"key":"2020021223485930900_REF45","doi-asserted-by":"crossref","unstructured":"Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 2004;103: 3303-3304.","DOI":"10.1182\/blood-2003-11-3845"},{"key":"2020021223485930900_REF46","doi-asserted-by":"crossref","unstructured":"Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet. 2003;4: 429-437.","DOI":"10.1016\/S1470-2045(03)01141-0"},{"key":"2020021223485930900_REF47","doi-asserted-by":"crossref","unstructured":"Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14: 238-247.","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/9\/3458\/1709450\/zh800905003458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/9\/3458\/1709450\/zh800905003458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T10:08:53Z","timestamp":1585908533000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/9\/3458\/21245\/Regional-intravascular-delivery-of-AAV2FIX-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-07-2908","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}